MDSpire - Summary
From the Journals

Mirtazapine Cuts Meth Use in Phase 3 Trial

Reduces days of use with no differences in depression, sleep, or quality of life

Share

In a phase 3 clinical trial involving 339 patients with moderate to severe methamphetamine use disorder, mirtazapine was shown to reduce methamphetamine usage days compared to placebo over 12 weeks. Conducted in Australia, participants taking mirtazapine reported a decrease of 7 days in methamphetamine use versus 4.8 days in the placebo group, translating to an 8% lower daily use risk. Although effective, the treatment was linked to more frequent adverse events such as drowsiness and weight gain. The findings suggest mirtazapine may be a viable option in outpatient settings to help manage methamphetamine dependence.

Original Source(s)

Mirtazapine Cuts Meth Use in Phase 3 Trial

  • by Andrea Surnit

  • April 1, 2026

Related Content

Bipolar Psychosis: Examining Diagnostic Boundaries

Investigators synthesize schizophrenia comorbidity and psychotic symptom profiles across bipolar populations.

Mental Health Content Accuracy Varies

Researchers found misinformation rates ranged from 0% to 57% across platforms and topics, with higher rates reported in several TikTok studies compared with YouTube.

GLP-1 Drugs Examined in Psychiatric Outcomes

Researchers evaluate mental health trajectories with antidiabetic therapies in patients with depression or anxiety.